Company profile: Propella Therapeutics
1.1 - Company Overview
Company description
- Provider of lymphatic-targeted oncology therapeutics and a lymphatic targeting drug delivery platform. Uses medicinal chemistry to adapt known actives with validated mechanisms for lymphatic delivery. Pipeline includes PRL-02 (abiraterone decanoate, intramuscular) for advanced prostate cancer, targeting the androgen receptor pathway by inhibiting CYP17, delivered via the lymphatic system to enhance efficacy and safety by bypassing the liver and reducing plasma exposure.
Products and services
- Lymphatic Targeting Platform: A platform-based drug delivery system that uses the lymphatic system to deliver high tissue concentrations, bypasses the liver, and reduces plasma exposure for oncology therapeutics
- Medicinal Chemistry Program: A medicinal chemistry–driven, custom-engineered discovery approach that creates oncology drugs from known actives with validated mechanisms of action and biological targets, integrating lymphatic targeting
- PRL-02 (abiraterone decanoate, intramuscular injection): A lymphatic-targeted drug candidate for advanced prostate cancer that blocks the CYP17 enzyme to suppress the androgen receptor pathway, aiming to improve efficacy and safety.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Propella Therapeutics
Sanarus
HQ: United States
Website
- Description: Provider of minimally invasive devices for the diagnosis and treatment of breast tumors, including the Visica treatment system for cryoablation of breast fibroadenomas; the Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and the ImarC tissue marker system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sanarus company profile →
GeminX Pharmaceuticals
HQ: Canada
Website
- Description: Provider of novel, targeted cancer therapeutics, dedicated to the discovery, development and commercialization of treatments based on research on the Bcl-2 cell death regulation pathway, including the discovery of GX15-070 (obatoclax), a novel small molecule.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeminX Pharmaceuticals company profile →
PharmaMar
HQ: Spain
Website
- Description: Provider of oncology medicines inspired by the sea, discovering antitumor molecules from marine organisms through integrated research and development. Delivers innovative products to equip healthcare professionals with new tools to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmaMar company profile →
Biofidelity
HQ: United Kingdom
Website
- Description: Provider of molecular diagnostic assays and platforms for rapid detection of target DNA sequences and actionable genomic biomarkers, with applications in oncology, prenatal testing, and infectious disease. Products include ASPYRE-Lung for guideline-recommended lung cancer biomarkers with results in days, and ASPYRE, a chemistry platform usable on existing PCR instruments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biofidelity company profile →
MiNK Therapeutics
HQ: United States
Website
- Description: Provider of allogeneic invariant natural killer T (iNKT) cell therapies and immune technologies, including AGENT-797 for solid tumors and severe ARDS; native iNKT therapies; engineered iNKT therapies with CARs and bispecific engagers; and platforms (CARDIS and IgG-based bispecific iNKT cell engagers) for discovering, optimizing, and developing targeted cancer treatments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MiNK Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Propella Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Propella Therapeutics
2.2 - Growth funds investing in similar companies to Propella Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Propella Therapeutics
4.2 - Public trading comparable groups for Propella Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →